P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate.
about
Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid LeukemiaKinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaIntracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cellsApplication of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemiaPTEN regulates BCRP/ABCG2 and the side population through the PI3K/Akt pathway in chronic myeloid leukemiaPredictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.Effectiveness of imatinib mesylate over etoposide in the treatment of sensitive and resistant chronic myeloid leukaemia cells in vitroWnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia.Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A.Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters.ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.Correlation between the type of bcr-abl transcripts and blood cell counts in chronic myeloid leukemia - a possible influence of mdr1 gene expression.CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicinThe bone marrow microenvironment as a sanctuary for minimal residual disease in CML.Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line.A novel co-operative mechanism linking TGFβ and Lyn kinase activation to imatinib resistance in chronic myeloid leukaemia cells.ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell LinesSimultaneous quantification of imatinib and its main metabolite N-demethyl-imatinib in human plasma by liquid chromatography-tandem mass spectrometry and its application to therapeutic drug monitoring in patients with gastrointestinal stromal tumor.Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1.Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).Association between the concentration of imatinib in bone marrow mononuclear cells, mutation status of ABCB1 and therapeutic response in patients with chronic myelogenous leukemia.ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia.The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2Strategies for overcoming imatinib resistance in chronic myeloid leukemia.Treatment options in imatinib-resistant chronic myelogenous leukemia.Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinibClinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia.Reversing multidrug resistance by tyrosine kinase inhibitorsSunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimersThe Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms
P2860
Q26781539-A2F211B5-E18C-4748-BDBB-5DE2F486FF29Q26849792-4744A014-90CF-4D55-9A33-23CB3EC0F7CCQ27025242-914FD087-BDF5-461E-A550-52A7B57DDD40Q28481327-229C17C2-A230-4B54-AFBF-2ECA7A766B28Q28534259-10C037F9-CCEA-4BB5-8388-F5C46D22AE48Q28540547-AB450793-BF62-48EC-A3CC-E26FA405D348Q33561227-3E9B20F6-C36E-4DAD-A677-B36E7C0F8940Q33566582-0C61EBBE-E141-42AC-B914-294A461D2EE3Q33602552-E8B3FFDC-CD0D-4D8A-B45B-1034AAB86ABDQ33744180-5C3F7317-6BF8-49D0-90E8-2061CFB4AC51Q33996893-70649D6E-CE93-4F03-B9AE-38281DFB363BQ34309928-B2BDCDE1-FD86-4DEB-BDA0-B79CD5727534Q35037415-9D978FF7-5750-48CF-A999-201236250DDBQ35141800-F85686BB-E0F8-41FB-BD8B-178D9ADBF6E7Q35171274-75D41F9C-70E1-4E0E-88A7-4233953E9BFBQ35615329-36DF62B0-1314-4C07-94AF-E6EB335F4F1CQ35717808-D09A4995-38EB-4905-A3F2-ED391608176FQ35773205-6366C4FB-C708-4A0F-B7EE-F044A875D8E4Q35816396-1DFE30B1-789B-40B2-8348-A91DD97774F8Q35930616-1A8F33D7-0C99-4350-BC6F-32D94F24192FQ35946822-8A39F89A-B522-4D42-BF44-FDD691095B41Q35991845-64F7B916-F5CA-46C6-851C-45C373D56003Q36071873-B17654C7-8F18-44E9-AF8D-432FE13514A3Q36106559-D1D65660-BC54-4388-A97D-891D84607C09Q36407123-C13EA0A8-3B7D-4F82-9F7B-DA9162DD3795Q36413392-139A2A5C-2F5F-428C-BAE2-8C6C44BE5771Q36579071-0E09F902-4CE7-4F82-AD6D-666B1B28FB7BQ36802620-566D5CAB-D8FC-4F5F-A6E5-C1B70A69A711Q36822880-32DD3ACB-2660-4646-A87C-A57E73FC5D07Q36825034-96F8B7B6-2E44-4BD7-B92F-930368F7FB3AQ36893545-0C589E8B-E5D7-489C-ABFA-3D0436849E6DQ36933169-3163D55D-BF41-442D-A57F-E437BD64C44BQ37027402-32F10E5F-F4FF-4921-9267-21F9F9F52E3FQ37062700-ADFEC507-CFC1-4ADF-8897-B565130B66F4Q37087238-2DF9CE02-285C-486F-A5DB-BC2E5706C914Q37132845-F68AAE6B-0232-4CC0-90AD-E7C709C68189Q37183670-2F511AE5-57D2-46B8-8B53-3D47EBB15231Q37188016-2DF9973A-F91F-41CE-B131-4CDE0766AF2FQ37199454-6ED2FF6E-F002-40FC-B90A-18633F2DF43EQ37289700-18115CB6-E6BF-435D-A17B-88A6DF03C3BA
P2860
P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
P-glycoprotein-mediated drug e ...... atment with imatinib mesylate.
@en
P-glycoprotein-mediated drug e ...... atment with imatinib mesylate.
@nl
type
label
P-glycoprotein-mediated drug e ...... atment with imatinib mesylate.
@en
P-glycoprotein-mediated drug e ...... atment with imatinib mesylate.
@nl
prefLabel
P-glycoprotein-mediated drug e ...... atment with imatinib mesylate.
@en
P-glycoprotein-mediated drug e ...... atment with imatinib mesylate.
@nl
P2093
P2860
P356
P1433
P1476
P-glycoprotein-mediated drug e ...... atment with imatinib mesylate.
@en
P2093
Bergemann T
Ehninger G
Freiberg-Richter J
Oelschlägel U
Platzbecker U
Schleyer E
von Bonin M
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403257
P577
2004-03-01T00:00:00Z